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Two million new cases of leishmaniasis occur every year, with the cutaneous leishmaniasis
(CL) presentation accounting for approximately two-thirds of all cases. Despite the high
incidence rates and geographic expansion of the disease, CL remains a neglected tropical
disease without effective intervention strategies. Efforts to address this deﬁcit have given
rise to the experimental murine model of CL. By virtue of its simplicity and pliability, the CL
model has been used to provide substantial information regarding cellular immunity, aswell
as in the discovery and evaluation of various vaccine adjuvants.The CLmodel has facilitated
in vivo studies of the mechanism of action of many adjuvants, including the TLR4 agonist
monophosphoryl lipid A, the TLR7/8 agonist imiquimod, the TLR9 agonist CpG, adenoviral
vectors, and the immunostimulatory complexes. Together, these studies have helped to
unveil the requirement for certain types of immune responses at speciﬁc stages of CL
disease and provide a basis to aid the design of effective second-generation vaccines for
human CL. This review focuses on adjuvants that have been tested in experimental CL,
outlining how they have helped advance our understanding of the disease and ultimately,
how they have performed when applied within clinical trials against human CL.
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INTRODUCTION
The leishmaniases, a group of diseases caused by infection with
various species of the protozoan parasite genus Leishmania, are
endemic in 88 countries. Together, ∼350 million people are at risk
of infection with these parasites with the leishmaniases having
an overall prevalence of 12 million cases worldwide and account-
ing for about 60,000 deaths annually (Desjeux, 2001). Expansion
of disease and the sharp rise in prevalence has been linked to
migration of non-immune people into endemic areas as well as
environmental changes resulting in the expansion of the insect
vector habitats (WHO, 2010). The latter, in particular, has the
potential to widen the geographic reach of the vector and intro-
duce leishmania transmission into previously unaffected areas.
Although an estimated 2 million new cases occur annually –
1.5 million cases of cutaneous leishmaniasis (CL) and 500,000
of visceral leishmaniasis (VL) – leishmaniases still represent a
neglected tropical disease and have not been considered as attrac-
tive vaccine targets by industry. Despite efforts that now spanmore
than a century, a licensed vaccine for use in humans is not yet
available.
Abbreviations: ALM, autoclaved Leishmania major; AS, Adjuvant Systems; BCG,
Bacille Calmette-Guérin; CL, cutaneous leishmaniasis; CLR, C-type lectin-like
receptors; DTH, delayed type hypersensitivity; GLA, glucopyranosyl lipid adju-
vant; IFN, interferon; IL, interleukin; ISCOM, immunostimulatory complexes; LPS,
lipopolysaccharide; MPL, monophosphoryl lipid A; Mtb, Mycobacterium tubercu-
losis; NO, nitric oxide; ODN, oligodeoxynucleotides; PAMP, pathogen associated
molecular patterns; PKDL,post-kala-azar dermal leishmaniasis; PRR,pattern recog-
nition receptor; rh, recombinant human; RIG, retinoic acid inducible gene based;
RLR, RIG-I-like receptors; SE, stable emulsion; SSG, sodium stibogluconate; TLR,
Toll-like receptor; TNF, tumor necrosis factor; VL, visceral leishmaniasis.
FIRST-GENERATION VACCINES FOR LEISHMANIASES
The earliest records of vaccination against leishmaniasis date back
several hundred years, when leishmanization was practiced in the
Middle East. Bedouin tribal societies traditionally exposed their
children to sandﬂy bites in order to protect them from facial
lesions. In some cases pus from active lesions was also inocu-
lated by excoriation of the recipient’s arm or thigh (Greenblatt,
1980). This technique was reﬁned in the early 1900s when culture
conditions were established for leishmania promastigotes, which
were then used to both prevent and treat active disease (Row,
1912; Wenyon, 1928; Greenblatt, 1980). These studies formed the
basis for large-scale vaccination trials that were carried out in the
Soviet Union, Israel, and Iran (Greenblatt, 1980; Nadim et al.,
1983). The success in these trials depended critically on the via-
bility and infectivity of the injected organisms. Organisms which
had lost virulence were shown to induce delayed-type hypersen-
sitivity but did not protect from subsequent natural infection.
Additionally use of live vaccines had many problems, including
the development of large uncontrolled skin lesions, exacerba-
tion of psoriasis, and other skin diseases, which paved the way
to trials using killed parasites but conﬂicting results made this
approach unpopular (Handman, 2001). However, this strategy
regained popularity in the late 1970s after the route of immuniza-
tion was found to be crucial for its efﬁcacy (Mayrink et al., 1979;
Greenblatt, 1980; Handman, 2001). Convit and colleagues used a
combination of killed L. mexicana or L. braziliensis promastigotes
and Mycobacterium bovis Bacille Calmette-Guérin (BCG) ther-
apeutically against leishmaniasis in South America. Vaccination
of clinically deﬁned patients appeared to induce a high cure rate
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even in severe cases and was accompanied by the development
of T helper type 1 (Th1) immune responses in the recipients
(Castes et al., 1989; Cabrera et al., 2000). Prophylactic vaccinations
with killed parasites formulated with or without BCG, however,
have been less successful (Armijos et al., 1998; Shariﬁ et al., 1998;
Momeni et al., 1999).
Although two of the most successful vaccines used to date
(against small pox and polio, respectively) are live pathogens, that
strategy does not appear feasible for leishmaniasis. Results from
several clinical trials using whole Leishmania (involving either
live or killed parasites) vary from 0 to 75% efﬁcacy against CL
(Coler and Reed, 2005; The Working Group on Research Prior-
ities for Development of Leishmaniasis Vaccines, 2011). Several
investigators are investigating the potential of live-attenuated vac-
cines for CL. Some genetically or chemically attenuated parasites
appear to persist indeﬁnitely without pathology and confer long
lasting protection in mice (Titus et al., 1995; Papadopoulou et al.,
2002; Uzonna et al., 2004; Davoudi et al., 2005; Daneshvar et al.,
2010; Birnbaumet al., 2012). Although not yet evaluated in clinical
trials, it is conceivable that these could offer lasting protection in
humans. Given their complex and heterogeneous nature, however,
it is unclear how they will overcome current vaccine regulations
and release criteria. Studies using these crude vaccine approaches,
though not ideal, have however proved that it is possible to induce
protection and suggest that this is also achievable with para-
site components. Several investigators have addressed this issue
using the experimental murine model of CL. The simplicity and
pliable nature of this model (differential outcomes dependent
upon mouse strain and infective dose) has permitted researchers
to address basic questions of immunity and have provided
signiﬁcant insight regarding the development of cellular immune
responses.
INSIGHT INTO CELLULAR IMMUNITY: THE CL MOUSE MODEL
Experimental murine infection with L. major has facilitated our
understanding of the Th1/Th2 paradigm, the development of
helper T cells during an infection and factors that regulate their
maintenance (Locksley and Scott, 1991; Scott, 1991; Reed and
Scott, 1993). Additionally, this model has revealed genetic mech-
anisms of protection conferred by Th1 cells in resistant strains
and susceptibility induced by Th2 cells in the BALB/c model
(Reed and Scott, 1993; Scharton-Kersten et al., 1995; Park et al.,
2000; Hutchins et al., 2005). Most inbred mouse strains (e.g.,
C57BL/6, CBA/J, and C3H) are considered resistant to infec-
tion with L. major. Upon intradermal/sub-cutaneous injection of
L. major, these strains develop as mall lesion that subsides within
6–8 weeks (Scott, 1998). Healing in resistant mice infected with
L. major is associated with the development of Th1 cells that pro-
duce IFN-γ, which is necessary for activation of macrophages and
the production of nitric oxide (NO), the key effector molecule for
destroying intracellular amastigotes (Liew et al., 1990a,b; Stenger
et al., 1994). These mice are also protected against additional
L. major challenges. In contrast, BALB/c mice are highly suscepti-
ble to L. major infection; parasite burdens can become extremely
high, with lesions progressing until ulceration. Deconstructing
the failure of BALB/c mice to protect against infection helped
to identify the crucial roles of IL-4 and IL-13 in the promotion
and expansion of Th2 cells. Both the initial development and
maintenance of Th1 cells in infected mice is dependent on the
presence of IL-12 produced by dendritic cells. Treatment of
BALB/c mice with recombinant IL-12 helps to protect against
infection while, conversely, treatment of resistant strains with
anti-IL-12 promotes the development of a Th2 response and
susceptibility (Heinzel et al., 1993, 1998; Hondowicz et al., 1997,
2000; Fernandez-Botran et al., 1999; Park et al., 2000; Kedzier-
ski et al., 2008). Another key cytokine that has been shown to
regulate disease outcome is IL-10. Disruption of the IL-10 gene
confers resistance while over-expression of this gene in resistant
strains renders them susceptible. IL-10 appears to mediate its
effect by blocking the activating effects of IFN-γ. In addition
to deactivating macrophages and inhibiting intracellular para-
site killing, IL-10 can also directly inhibit Th1 cell development
and their production of IFN-γ (Kane and Mosser, 2001). Further-
more, IL-10 production by natural CD4+CD25+ regulatory T cells
plays an important role in disease pathology (Belkaid et al., 2002a;
Mendez et al., 2004).
Importantly, given its ﬂexibility and broad understanding, the
CL mouse model has helped construct a syllogism that supports a
platform for adjuvant discovery/selection. By virtue of its simplic-
ity, it has also facilitated the study themechanismof action of these
adjuvants in vivo (Mendez et al., 2003; Darrah et al., 2007, 2010).
Among the adjuvants investigated using this model are the TLR4
agonist-monophosphoryl lipid A (MPL), the TLR7/8 agonist –
imiquimod, the TLR9 agonist – CpG, and the immunostimulatory
complexes (ISCOM; Figure 1). There is some irony that very few
of these adjuvants have actually been evaluated against human CL,
although this lack of progression is at least partially attributable to
the fact that human CL is a much more complex disease than the
experimentalmodel. These adjuvants have, however, helped scien-
tists understand the need for certain types of immune responses
at speciﬁc stages of disease, which in turn, could aid in design-
ing an effective vaccine for human CL. This review focuses on
adjuvants that have been tested in experimental CL, their effects
when applied in human CL, and how they have helped advance
our understanding of the disease.
ADJUVANT BIOLOGY AND THE ADVANCEMENT TOWARD
SECOND GENERATION VACCINES
Innate immunity forms the host’s ﬁrst line of defense against
microbial invasion. Targeting innate immune receptors with adju-
vants is a logical strategy, particularly for infections of innate
cells such as leishmaniasis. Studies of adjuvants began more than
a hundred years ago with the discovery that an acute bacte-
rial infection could induce regression in a concurrent malignant
tumor (Tokunaga, 1980; Bickels et al., 2002). Surprisingly how-
ever, the “immunologist’s dirty little secret” (or rather the killed
M. tuberculosis) present in Freund’s adjuvant was almost taken
for granted until 1989 when Charles Janeway Jr. declared that
“the innate immune response (it induced) was prerequisite for an
adaptive immune response” (Janeway, 1989). Janeway’s prediction
was eventually proven by a number of labs using classical genetic
methods, most clearly when TLR4 was identiﬁed as the receptor
for lipopolysaccharide (LPS), and TLR9 was shown to recognize
bacterial DNA (Poltorak et al., 1998; Hemmi et al., 2000; Duthie
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FIGURE 1 |Toll-like receptor agonists as adjuvants. All pathogens
including bacteria, viruses, and protozoans induce activation of antigen
presenting cells (APC) resulting in the production of IL-12. Adjuvant biology
relies on this same approach by usingTLR agonists that have been derived
from these organisms to induce IL-12 production. The induction of IL-12
helps generate a strongTh1 response and inhibit Th2 responses, a key
component in battling intra-cellular infections such as Leishmania.
et al., 2011). The identiﬁcation of pathogen associated molecular
patterns (PAMPs; a group of lipid, carbohydrate, peptide, and
nucleic-acid structures, broadly expressed by different microor-
ganisms) and their associated pathogen-recognition receptors
(PRRs), has revolutionized vaccine research (Janeway, 1989;
Tokunaga et al., 1999; Bickels et al., 2002; Janeway and Medzhi-
tov, 2002; Medzhitov and Janeway, 2002; Pashine et al., 2005;
Medzhitov, 2009; Reed et al., 2009). Directed stimulation of PRR,
which include the Toll-like receptors (TLRs), C-type lectin-like
receptors (CLRs), cytosolic nucleotide oligomerization domain-
like receptors, and retinoic acid inducible gene based (RIG)-I-like
receptors (RLRs), can trigger different types of immune responses
(Janeway and Medzhitov, 2002; Medzhitov and Janeway, 2002;
McGreal et al., 2005; Carneiro et al., 2007; Kawai and Akira, 2007;
Onomoto et al., 2007). Interaction between PRRs and their cog-
nate PAMPs initiates a complex cascade of intracellular signaling
pathways leading to the production of cytokines, chemokines,
and type I IFNs that mediate the induction of inﬂammatory
and antimicrobial responses. This process activates an adaptive
immune response tailor-made to the invading microbe. These
PAMPs, speciﬁcally those binding the TLRs, are the basis of many
adjuvants. In addition, cytokines, bacterial toxins, and glycol-
ipids released during or after PRR engagement are also being
used as adjuvants to elicit immune responses (Pashine et al., 2005;
Reed et al., 2009; Duthie et al., 2011). Advances in molecular and
cellular biology are rapidly revealing the nature of innate immu-
nity and adjuvant activity. The discovery of the ability of adjuvants
to enhance disease-speciﬁc immune responses using recombi-
nant antigens has led many researchers to re-focus their vaccine
development programs (Reed et al., 2009). Effective adjuvants
and adjuvant formulations can utilize multiple compounds and
mechanisms to achieve the desired immunological enhancement
(Schijns, 2000; Pashine et al., 2005; Reed et al., 2009). These mech-
anisms can enhance antigen presentation, leading to induction of
effective humoral (B cell) and cellular (CD4 and/or CD8 T cell)
responses.
Despite the dramatic advances in our understanding of deﬁned
PRR, the majority of the vaccines that have been licensed and
made available for clinical use remain live, attenuated, or killed
vaccines (WHO, 2004; The European Medicines Agency, 2005;
WHODepartment of Immunization,Vaccines andBiologicals and
UNICEF Programme Division, Health Section, 2005; National
Advisory Committee on Immunization, 2008; Central Drugs
StandardControlOrganization,2010; U.S. Food andDrugAdmin-
istration, 2011). An ideal vaccine against leishmaniasis must be
safe, effective, and given its recognition as a neglected disease,
affordable. As addressed earlier, it appears that a live or killed par-
asite vaccine will not be feasible for leishmaniasis. An inherent and
major advantage of vaccines based on attenuated pathogens and
inactivated viruses or bacteria is that they are sufﬁciently immuno-
genic without additional adjuvants, likely through the undeﬁned
inclusion of intrinsic PAMPs. Such activity has been revealed for
the highly effective Yellow Fever vaccine (Querec et al., 2006). By
contrast, protein-based vaccines, although offering considerable
advantages over traditional vaccines in terms of safety and cost of
production, are often less immunogenic.
Over the past few decades, many researchers have searched for
genes encoding leishmanial proteins that are linked to the protec-
tive response and can induceprotection againstCL in experimental
models (Handman et al., 1995; Mougneau et al., 1995; Skeiky et al.,
1995a,b, 1997, 1998; Webb et al., 1996, 1997; Probst et al., 1997;
Campos-Neto et al., 2002; Coler et al., 2002). Identifying candi-
date antigens alone, however, is not sufﬁcient as they need to be
characterized to ensure quality and stability. More importantly,
candidate antigens need to be delivered with appropriate adju-
vants to elicit an appropriate immune response (Coler and Reed,
2005; Reed et al., 2009). A signiﬁcant research effort has focused
on adjuvants in CL (Table 1). This review outlines the efforts
of several labs, including our own, regarding the use of adju-
vants both in CL animal models and their impact on efﬁcacy in
the clinic.
ALUMINUM SALTS (ALUM) AS ADJUVANT
Introduced in the 1920s, alum became the ﬁrst adjuvant to be
approved by the U.S. Food and Drug Administration for use in
humans (White et al., 1955; Marrack et al., 2009; Reed et al., 2009).
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Table 1 | List of adjuvants that have been used in experimental
and/or clinical CL.
Adjuvant Antigen Murine CL Human
Alum +/− BCG ALM ++ Phase I/II
Alum +/− CpG SLA ++ ND
Based onTLR4 agonists
MPL-SE GP63 −/− ND
L111f, L110f ++ Phase I/II
SMT, KSAC ++ ND
GLA-SE L110f, NS, KSAC ++ Phase I
Based onTLR7/8 agonists
Imiquimod (Aldara) N/A ++ Phase II
R848 ALM ++ ND
ALM ++ ND
Based onTLR9 agonists
CpG Live parasite ++ ND
SLA ++ ND
ALM ++ ND
H2B ++ ND
LRP ++ ND
rLiP0 +− ND
LACK ++ ND
LmSTI1 ++ ND
L111f ++ ND
ND, not done; ++, protection; +/−, incomplete protection.
Although the initial and long-held theory was that alum facilitated
an immune response by providing a depot, more recent studies
have challenged this theory and suggest otherwise (White et al.,
1955; Gupta et al., 1996). Studies by Brewer et al. (1999) indicated
that alum boosted humoral immunity by providing Th2 cell help
to follicular B cells. Additional properties of alum were revealed
recently by the demonstration that it can induce the production of
monocyte and granulocyte chemoattractants and enhance mono-
cyte differentiation into dendritic cells (Kool et al., 2008; Seubert
et al., 2008). It is now apparent that alum can act through both
NLRP3-dependent and -independent pathways to induce type 2
inﬂammatory responses, characterized by the accumulation of
eosinophils at the site of injection and the enhanced production
of antigen-speciﬁc IgE and IgG1 (Li et al., 2007, 2008; Eisen-
barth et al., 2008; Reed et al., 2009; Kuroda et al., 2011; Marichal
et al., 2011). A number of vaccines, including whole parasite vac-
cines and recombinant vaccines such as those for Hepatitis B and
human papilloma virus, have been developed using alum with the
intent of eliciting protective antibody responses (WHO Depart-
ment of Immunization, Vaccines and Biologicals and UNICEF
Programme Division, Health Section, 2005). A major advantage
of alum is its ability to enhance humoral immunity with mini-
mal side-effects. Additional beneﬁts include, stabilization of the
associated antigens with alum (because formulation is achieved
through adsorption of antigens onto highly charged aluminum
particles) and the relative simplicity to produce on a large scale.
To date, the alum adjuvant delivery system has been used in over
80% of vaccines administered worldwide. The inability of alum to
elicit cell-mediated Th1 or CTL responses required for the control
of most intracellular pathogens (such as Leishmania) is a major
limitation. Alum has, however, been used as a carrier/vehicle for a
number of new age adjuvants including IL-12, GM-CSF,CpG, and
MPL (Kenney et al., 1999; Stacey and Blackwell, 1999; Tonui et al.,
2004; Kundi, 2007; Frazer and Levin, 2011). Most importantly,
the recent approval of MPL-Alum for two different vaccines,
Fendrix and Cervarix, has set precedence for the use of TLR4
agonists within human vaccines (Kundi, 2007; Duthie et al., 2011;
Frazer and Levin, 2011).
In relation to leishmaniasis, alum has been used in combi-
nation with BCG or IL-12 and autoclaved L. major (ALM) to
protect against experimental murine CL (Kenney et al., 1999;
Soudi et al., 2011). The ﬁrst clinical study in leishmaniasis that
used alum in conjunction with ALM and BCG was conducted
for the treatment of VL. Data indicated that the approach was
not only safe but could induce strong delayed type hypersensi-
tivity (DTH) reactions in study volunteers (Kamil et al., 2003).
More recently, alum-precipitated ALM and BCG was used as
part of an immunochemotherapeutic approach to treat post-
kala-azar dermal leishmaniasis (PKDL) in Sudan (Musa et al.,
2008). This randomized and double-blind study aimed to assess
safety, immunogenicity, and curative potential of this regimen
in patients with persistent PKDL. Patients were treated with
sodium stibogluconate (SSG)+ alum-precipitatedALMandBCG.
SSG + alum/ALM + BCG was found to be safe and immuno-
genic, and demonstrated signiﬁcant healing potential in persistent
PKDL lesions.
The applicability of alum-based formulations for leishmania
vaccines is neither supported by current knowledge regarding
alum’s mechanism of action nor by clinical or experimental
experience.
INTERLEUKIN-12
Interleukin-12, originally called natural killer cell stimulatory
factor, was identiﬁed by Trinchieri and colleagues, who discov-
ered that it can stimulate the production of IFN-γ from T cells
and natural killer cells (Kobayashi et al., 1989; Chan et al., 1991;
Manetti et al., 1993). Further studies demonstrated the ability
of several pathogens to induce a Th1 response correlated with
their capacity to stimulate the production of IL-12 (Hsieh et al.,
1993; Scott, 1993). The critical involvement of IL-12 in promot-
ing Th1 responses in vivo was demonstrated using the mouse
model of CL (Sypek et al., 1993). The use of IL-12 as an adju-
vant was subsequently examined in various models including the
murine CL model (Sypek et al., 1993; Scott and Trinchieri, 1997;
Wright et al., 2008; Metzger, 2010). Effective vaccination against
L. major in susceptible mouse strains was achieved using recom-
binant IL-12 with soluble leishmanial antigen (SLA) and with a
recombinant LACK protein (Afonso et al., 1994; Mougneau et al.,
1995). Several studies have demonstrated the short-lived nature
of protection in mice following immunization with recombinant
LACK plus IL-12 protein. Protection waned 2 weeks after immu-
nization, whereas protection was sustained up to 12 weeks later
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when the IL-12 and LACK genes were deliveredwithin aDNA con-
struct (Gurunathan et al., 1997, 1998; Stobie et al., 2000; Mendez
et al., 2001). These studies suggested that the continuedpresence of
IL-12 as a requirement for long-lived vaccine-induced immunity.
The safety, immunogenicity, and efﬁcacy of a vaccine com-
bining heat-killed L. amazonensis with recombinant human (rh)
IL-12 and alum (aluminum hydroxide gel) as adjuvant, has been
assessed in rhesus macaques. When lesion development was fol-
lowed after intradermal challenge, an IL-12 dose response was
evident and protective immunity was demonstrated in all mon-
keys (12 total) that received 2 μg rhIL-12 at all Ag/alum doses
(Kenney et al., 1999). When vervet monkeys were immunized
with ALM with or without rhIL-12, despite the generation of
substantial Leishmania-speciﬁc immune responses, no protection
was observed against subsequent challenge with L. major parasites
(Gicheru et al., 2001). The transition to use of rhIL-12 in humans
has proven difﬁcult, however, as parenteral administration over
several days was found to be highly toxic (Cohen, 1995; Wright
et al., 2008).
TLR4 AGONISTS – LIPID A AND DERIVATIVES
Lipopolysaccharide, a complex amphipathic molecule that cov-
ers the outer surface of Escherichia coli and other Gram-negative
bacteria such as M. tuberculosis was the ﬁrst microbial product
discovered to be a TLR agonist. Although lipid A had been deﬁned
as the hydrophobic moiety of LPS for over 50 years, the elucida-
tion of lipid A biosynthesis was not achieved until the early 1980s.
The ability of the “free” lipid A molecule to induce tumor regres-
sion, endotoxic shock, interferon production, and macrophage
activation generated much pathophysiological interest (Takayama
et al., 1983). Determination of the lipid A structure was fol-
lowed by attempts to chemically modify lipid A, generally with
the intent of uncoupling its toxic effects from its potentially useful
immunomodulatory properties. This resulted in the identiﬁcation
of an acylated diglucosamine derivative of lipid A from Salmonella
minnesota RC595, which was then further reﬁned to derive MPL
with reduced pyrogenicity (Persing et al., 2002).
Even though the existence of LPS receptors had been identiﬁed
in the 1970s to be dependent on the integrity of a single locus
known as Lps, the locus was not deﬁned until 1998, when it was
demonstrated through positional cloning to be identical to the
TLR4 (Tlr4) locus6 (Skidmore et al., 1976; Poltorak et al., 1998).
TLR4’s ability to utilize both the MyD88 and TRIF signaling path-
ways has been critical to the success of lipid A as an adjuvant.
While it is not clear if a single TLR4 molecule can signal through
one or both pathways at the same time, it has been suggested that
MyD88/MAL is required for the rapid activation of TLR4 signal-
ing and for the production of TNF,while TRAM stimulates a more
sustained induction of NF-κB through the MyD88-independent
pathway. Studies with MyD88 KO and TRIF KO mice have indi-
cated that signaling through MyD88/MAL is essential for IL-12
production, and the resulting IFN-γ, while signaling through the
TRIF/TRAM pathway appears to be crucial for IL-6 production.
Further research deﬁning the roles of these two signaling pathways
in TLR4 activation is required (O’Neill and Bowie, 2007).
The efﬁcacy of MPL was ﬁrst tested in a syngeneic guinea
pig cancer model, where it synergistically enhanced the ability
of mycobacterial cell wall skeleton (CWS) to regress trans-
plantable, line-10 tumor (hepatocellular carcinoma; Ribi et al.,
1984). Later studies demonstrated that MPL can also enhance
immune responses to both killed virus and puriﬁed proteins
(Masihi et al., 1986). Based upon those studies adjuvanting a mix-
ture of well-deﬁned recombinant antigens together with MPL was
a logical progression for a vaccine against leishmaniasis.
Monophosphoryl lipid A was ﬁrst evaluated against leishma-
nia by comparison against alternative adjuvants in a prophylactic
study in the murine model of CL with L. mexicana with a subunit
vaccine (Aebischer et al., 2000). The ability of MPL to adjuvant
antigen-speciﬁc protection against experimental CL was con-
trasted against a panel of ﬁve other adjuvants (IL-12, QS-21,
M. bovis BCG, Corynebacterium parvum – now known as Propi-
onibacterium acnes, and Detox). By its ability to protect against
CL infection, Detox, an adjuvant formulation made up of MPL
and mycobacterial CWS, was shown to be almost equal in efﬁ-
cacy to IL-12. MPL alone induced similar results, albeit with a
slightly lower efﬁcacy than either Detox or IL-12. In later stud-
ies conducted at IDRI, MPL was formulated in an oil-in-water
formulation (MPL-SE) which helped improve its efﬁcacy (Coler
and Reed, 2005). Several studies have demonstrated that the inclu-
sion of MPL-SE induces a strong type 1 proﬁle, with high levels
of IFN-γ and comparatively low levels of type 2 cytokines such
as IL-4 and IL-10. Serum immunoglobulin also becomes skewed
toward a higher IgG2a/IgG1 ratio when MPL is present in the
vaccine formulation (Coler and Reed, 2005). Further, use of MPL
within prophylactic vaccines can induce multi-functional, mem-
ory T cells, an established correlate of protection in the murine CL
model (Darrah et al., 2007; Bertholet et al., 2009). Moreover, this
adjuvant has shown equivalent efﬁcacy in both murine CL andVL
models (Coler et al., 2007; Goto et al., 2007).
Of theTLR agonists identiﬁed,MPL is themost advanced and is
currently the only licensed adjuvant commercially available today.
MPL adjuvant has proven to be a potent yet apparently non-toxic
vaccine adjuvant when administered with heterologous antigens.
MPL has been used extensively as an adjuvant in clinical trials for
several infectious disease and cancer indications, and to date, over
100,000 doses of MPL have been administered to human subjects.
The safety proﬁle is similar to that of alum. The adjuvant system
AS04 (GlaxoSmithKline Biologicals), a combination of aluminum
salts and MPL has been approved in both Europe and the United
States. Licensed AS04 containing vaccines, Fendrix and Cervarix
confer protective immunity against hepatitis B virus or human
papilloma virus, respectively. Approval of Cervarix in 2009 made
MPL the ﬁrst deﬁned adjuvant to be licensed for use in vaccines in
the United States. AS04 has now been shown to induce a transient,
localized innate immune response and activation of DCs, lead-
ing to activation of antigen-speciﬁc T cells and enhanced adaptive
immunity (Didierlaurent et al., 2009). As predicted by its abil-
ity to induce IL-12, despite the presence of alum, inclusion of
MPL in AS04 biases the immune response to a strong Th1 type
phenotype.
IDRI has also used MPL to spearhead several clinical trials
directed against leishmaniasis. Our ﬁrst trial investigated a mix-
ture of antigens for the ability to treat drug-refractory patients
suffering from mucosal leishmaniasis (ML; Badaro et al., 2006).
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The trial was successful with ﬁve/six patients showing complete
clinical remission at the 9-month follow-up and all six becoming
asymptomatic at the 5-year follow-up examination. The antigens
had been adjuvanted with GM-CSF at that time but adjuvant
was subsequently switched to MPL-SE based practical issues and
on results from our pre-clinical studies (Coler and Reed, 2005).
The antigens are now expressed as a single entity within Leish F1
chimeric fusion protein, rendering the antigen conﬁgurationmore
accessible to cost-effective, large-scale production. This vaccine
was tested in both healthy Columbian and Indian volunteers with
either no history of leishmaniasis or sub-clinical infection with
L. braziliensis/L. panamensis (detection based on the Montenegro
skin test). An increase in anti-Leish F1 IgG response was observed
in all, and an antigen-speciﬁc IFN-γ response was observed in the
majority of recipients (Velez et al., 2009; Chakravarty et al., 2011;
Duthie et al., 2012). Based on these results we concluded that the
vaccine was safe and well-tolerated in subjects with and with-
out evidence of prior infection. Additionally, we have evaluated
the LEISH-F1 + MPL-SE vaccine as an adjunct immunotherapy
with standard chemotherapy in both CL and ML. The vaccine was
found to be safe and immunogenic in both CL and ML patients
and appeared to shorten their time to cure when used in com-
bination with meglumine antimoniate chemotherapy. Further
treatment of ML patients with vaccine helped induce a mem-
ory T cell subset, associated with clinical cure (Llanos-Cuentas
et al., 2010). These studies have proven that the vaccine is safe
for use in both healthy and infected patients, and is able to
induce a memory response that could help protect against future
infections.
We have further optimized the adjuvant MPL by develop-
ing a synthetic lipid A derivative that eases manufacture and
provides a more homogenous ﬁnal product. Like MPL, for-
mulations of glucopyranosyl lipid adjuvant (GLA) also signals
through TLR4 (Coler et al., 2011). When formulated with SE,
an oil-in-water emulsion, and mixed with antigen, the result-
ing Ag + GLA-SE mixture induces potent Th1 immune response
in mice. Studies show that GLA-SE and MPL-SE adjuvanted
responses to be dose-dependent, skewing toward a Th1-like
response in mice that receive either of these TLR4 agonists. We
have also established that GLA-SE is a more potent adjuvant
compared to MPL-SE in terms of stimulating antigen-presenting
cell activation and inducing greater IFN-γ secretion by antigen-
speciﬁc T cells. Low doses of GLA-SE are capable of inducing
a high frequency of multi-functional effector T cells (Bertholet
et al., 2009). Recent work has also suggested that either TLR4-
based adjuvant (MPL and GLA) represent good candidates for
CL immunotherapy when coupled with the TLR9 ligand, CpG
(Raman et al., 2010). Together, these data indicate considerable
promise for the development of a safe, effective, and inexpensive
vaccine for both prophylactic and therapeutic application against
leishmaniasis.
TLR7/8 AGONISTS – RESIQUIMOD AND IMIQUIMOD
Initial characterization studies had demonstrated that imiquimod
could induce production of antiviral cytokines, including IFN-α,
TNF, and IL-1β, from monocytes (Testerman et al., 1995).
Imiquimod could also augment the Th1 immune response by
mediating the release of IL-12 and IFN-γ from macrophages
(Wagner et al., 1999). It was revealed, that treatment of L. dono-
vani-infected macrophages with imiquimod resulted in killing
of intracellular amastigotes and that this was dependent on the
production of NO by the treated macrophages (Buates and Mat-
lashewski, 1999). Through a gene array approach it was further
demonstrated that, consistent with the ability of imiquimod
to activate killing of intracellular Leishmania amastigotes,
imiquimod’s related compound S-28463 induced gene expres-
sion associated with macrophage activation and an inﬂammatory
response including NF-κB, IL-1, iNOS, and MIP-1 (Buates and
Matlashewski, 2001). Only later was it discovered that imiquimod
structurally resembled single stranded RNA that was capable of
activating macrophages through stimulating the TLR7 pathway
(Hemmi et al., 2002).
Based on these experimental observations and because topical
treatment with imiquimod had obtained FDA approval in 1997
(for the treatment of cutaneous cervical warts caused by human
papilloma viruses infections), a small human trial was conducted
to treat CL patients (Arevalo et al., 2001). This study, supported
by WHO-TDR was conducted in Peru on 12 CL patients infected
with L. V. braziliensis that had failed an initial treatment with pen-
tavalent antimony. Study subjects were given a second course of
pentavalent antimony plus topical imiquimod every 2 days for 20
days. The topical application of imiquimod on the lesions was
well tolerated and 11 out of 12 patients were cured at the 3-month
follow-up period (Arevalo et al., 2001). Subsequently a placebo
controlled study was conducted on 40 CL patients who had failed
treatment with pentavalent antimony and were given a second
treatment with the combination of pentavalent antimony plus
topical imiquimod or a placebo cream. The outcome was a 72%
cure rate for the group receiving imiquimod versus 35% cure for
the group receiving placebo at the 3-month follow-up (Miranda-
Verastegui et al., 2005). Overall these observations indicated that
combination therapy with topical imiquimod plus pentavalent
antimony was well tolerated and this represented a good option
for treating patients who had failed the ﬁrst line treatment with
pentavalent antimony alone.
A subsequent study was undertaken to determine whether
topical imiquimod combined with pentavalent antimony could
be considered as a ﬁrst line therapy for CL in Peru (Miranda-
Verastegui et al., 2009). This randomized placebo control study
showed that the combination treatment of imiquimod plus pen-
tavalent antimony performed better (75% cure) than placebo
plus pentavalent antimony (58% cure) at the 3-month follow-
up period, but that the difference was not statistically signiﬁcant.
A study conducted in Iran involving L. tropica infections reported
that there was no beneﬁcial effect of combining topical imiquimod
with pentavalent antimony (Firooz et al., 2006). It is possible that
the topical imiquimod was unable to penetrate to the infected cells
because, in comparison to the ulcer lesions typical of New World
CL, L. tropica infections are typically nodular.
An interesting recent report describes the treatment of a 7-year-
old boy with a lesion on the left cheek caused by a L. infantum
infection (Hervas et al., 2011). For more than a year this patient
had failed various treatments, including topical paromomycin,
intralesion injection of pentavalent antimony, photodynamic
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therapy, and two courses of intravenous liposomal ampho-
tericin B. The patient was ﬁnally treated with topical imiquimod
and cured within a month (Hervas et al., 2011). Treatment with
topical imiquimod alone was attempted on L. V. braziliensis infec-
tions in Peru and although this provided initial lesion regression,
complete cure was not obtained (unpublished observation). For
this reason, imiquimod has typically been used in combination
therapy in the New World. Based on the available published evi-
dence, a World Health Organization appointed expert committee
on control of leishmaniasis recently updated it treatment guide-
lines to now include the use of imiquimod in combination with
pentavalent antimony as a second-line therapy for CL in the New
World (WHO, 2010).
Given the adjuvant properties of topical imiquimod in treat-
ment of infectious diseases, topical imiquimodhas also been tested
as a vaccine adjuvant in an experimental model of CL in BALB/c
mice. It was found that application of topical imiquimod on
the skin prior to subcutaneous immunization with crude Leish-
mania antigen provided increased protection against challenge
infection compared to immunization of crude antigen alone and
this was associated with an enhanced Th1 response against the
vaccine antigen (Zhang and Matlashewski, 2008). Subsequently,
it was likewise shown that topical application of imiquimod at
the site of subcutaneous injected Plasmodium falciparum cir-
cumsporozoite (CS) peptide elicited a strong Th1 response and
high antibody titers that provided protection against a challenge
infection (Othoro et al., 2009). These studies show that further
consideration should be given to using topical imiquimod as a vac-
cine adjuvant for any pathogen antigen delivered subcutaneously,
particularly where a Th1 response is required for protective
immunity.
TLR9 AGONISTS – CpG AND IMMUNOMODULATORY OLIGOS
The concept of immunostimulatory DNA was ﬁrst identiﬁed in
the early 1980s during studies on BCG-mediated tumor resistance
(Tokunaga et al., 1999). The identiﬁcation of CpG dinucleotide
motifs within prokaryotic DNA that could activate B cells galva-
nized research efforts (Krieg et al., 1995). The adjuvant properties
of CpG were exploited within experimental vaccines for a num-
ber of diseases including lymphoma, hepatitis, malaria, inﬂuenza,
and leishmania well before the discovery of its innate receptor,
TLR9, in 2000 (Lipford et al., 1997b; Wooldridge et al., 1997;
Brazolot Millan et al., 1998; Davis et al., 1998; Moldoveanu et al.,
1998; Zimmermann et al., 1998; Jones et al., 1999; Hemmi et al.,
2000). These ﬁndings also provided an additional dimension to be
explored, i.e., the possibility of intentionally incorporating these
motifs within DNA vaccines (Klinman et al., 1997; Li et al., 2004).
While it was ﬁrst believed that a single type of optimal CpG motif
would work in all applications, later reports showed that speciﬁc
motifs of CpG-containing immunostimulatory oligodeoxynu-
cleotides (CpG ODNs) could vary dramatically in their ability to
induce individual immune effects (Ballas et al., 2001; Krug et al.,
2001). Three classes of CPG ODN are now recognized – A-class
ODN promote the highest degree of NK cell stimulation and also
IFN-α secretion by plasmacytoid DCs; B-class ODN stimulate
strong B cell andNK cell activation, as well as cytokine production;
C-class ODN combine the effects of A- and B-class CpG ODN.
The ability of CpG ODN to stimulate macrophages and dendritic
cells to synthesize several cytokines, including IL-12, IL-18, TNF-α,
and IFNs (IFN-α, IFN-β, and IFN-γ), to upregulate costimulatory
molecules such asCD40 andMHCclass II, and to enhance the abil-
ity of dendritic cells to present soluble protein to class I-restricted
T cells, make CpG ODN a good option as an adjuvant (Klinman
et al., 1996, 2000).
Initially, the CL mouse model was used to showcase the ability
of CpG ODNs to switch the Th2 response associated with the dis-
ease to a strong Th1 response. This switch has now been associated
with IL-12-dependent production of IFN-γ, an attractive quality
for a CL vaccine (Lipford et al., 1997b; Zimmermann et al., 1998;
Walker et al., 1999; Fukao et al., 2002; Flynn et al., 2005; Hutchins
et al., 2005; Yang et al., 2010). The ﬁrst studies using CpG ODNs
as an adjuvant within prophylactic vaccines for CL demonstrated
that inclusion of CpG helped to induce long-term immunity that
protected against the parasite (Stacey and Blackwell, 1999; Walker
et al., 1999). Further studies demonstrated that this protection is
reliant onCD4 andCD8T cell help, both of which had been shown
to be important in L. major infection and induced when CpG was
used as an adjuvant (Lipford et al., 1997a; Belkaid et al., 2002b;
Rhee et al., 2002).
Later studies by Mendez et al. (2003), showed that mice vac-
cinated with live parasites plus CpG ODNs displayed a transient
inﬂammation at 3–5 weeks, after which time little or no dermal
pathology was observed. The resolution of the transient inﬂam-
mation and parasite-burden in the ears of CpG ODN-treated mice
coincidedwith the decrease of CD4T cells in the site, whereas these
cells began to accumulate in the ears of unvaccinated mice by 6
weeks after L. major infection. These responses are induced via
activation of dermal DCs acting in an IL-6 dependent manner
(von Stebut et al., 1998; Wu et al., 2006). Activation of these der-
mal DCs eliminates the silent phase of the infection by altering
the natural kinetics of Treg cell accumulation that usually occurs
in the skin after L. major challenge (Belkaid et al., 2000, 2002a;
Wu et al., 2006). Recently, the same group reported the unusual
IL-2 production by CD11c+ DCs in the skin of mice vaccinated
with Lm/CpG. This unusual secretion was concomitant with a
peak in IFN-γ-producing NK cells and CD4+ T cells and the
control of parasite growth (Laabs et al., 2009). It has now been
shown that inclusion of CpG ODN in the vaccine also enhances
the proliferation of Th17 cells, which in turn aids the develop-
ment of a protective cell-mediated immunity against the parasite
(Wu et al., 2010). The Th17 response was shown to be dependent
upon release of vaccine-induced IL-6 identiﬁed in earlier studies
(Wu et al., 2006). Neutralization of IFN-γ and, in particular, IL-17,
caused increased parasite burdens in Lm/CpG-vaccinated mice.
IL-17R-deﬁcient Lm/CpG-vaccinated mice developed lesions, and
despite displaying normal IL-12 levels, showed a decrease in IFN-γ
production. Neutrophil accumulationwas also decreased in the IL-
17R-deﬁcient Lm/CpG-vaccinated mice but the number of Treg
increased. The most striking observation in all these studies was
that mice treated with CpG ODNs had increased levels of IL-10 in
their draining lymph nodes, and only a transient increase in the
number of Tregs at the site of infection, compared to control ani-
mals (Mendez et al., 2003; Wu et al., 2006). Thus, vaccination with
live parasites andCpGODNs appears to not only enhance adaptive
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immunity but also to modulate the response of innate immune
cells, thereby inhibiting parasite growth and the development of
vaccine-induced pathology.
Interestingly, CpG ODNs induce similar responses even when
mixed with recombinant antigens (Rhee et al., 2002; Coler and
Reed, 2005; Darrah et al., 2007). Vaccination with CpG ODN
induced a high frequency of multi-functional T cells, a positive
correlate of protection, especially in the CL model. Responses
generated with these deﬁned vaccines were established as early as
10 days after immunization, suggesting CpG ODN could be good
adjuvants for both prophylaxis and therapy (Darrah et al., 2007;
Raman et al., 2010). These responses were shown to remain consis-
tent over prolonged periods of time, although they did wane after
6 months (Rhee et al., 2002; Darrah et al., 2007). Further investiga-
tions showed an increase in IL-10 levels in sera after immunization
with vaccines containing CpG ODNs (Darrah et al., 2010). Inhibi-
tion of innate IL-10 produced by antigen presenting cells (APCs)
at the time of immunization signiﬁcantly enhanced the magni-
tude of the response and the extent of Th1 differentiation and,
importantly, increased protection. This particular aspect of the
adjuvant makes it much more attractive option for immunother-
apy, with the possibility of preventing pathology. Studies
performed by IDRI demonstrate that treatment of L. major-
infected mice with CpG in conjunction with L110f and MPL-SE,
decreases both parasite burden and infection-induced pathology
(Raman et al., 2010).
CpG ODN have not yet been used as a vaccine adjuvant against
leishmaniasis in human subjects. Preliminary studies involving
vaccination of non-human primates with vaccine formulations
containing CpG ODN have yielded positive results, inducing
strongTh1 responses in both prophylactic and therapeutic settings
(Walker et al., 1999; Flynn et al., 2005).
Several synthetic ODN are currently in development for the
treatment of various cancers (Krieg, 2008). These ODNs use
a nuclease-resistant phosphorothioate backbone that improves
the half-life in the body from just a few minutes (for unmod-
iﬁed native DNA) to approximately 48 h. Immune modulatory
oligonucleotides (IMOs) that stimulate TLR9 signaling have been
developed and tested, for anti-tumor activity in mouse models,
both as a monotherapy and in combination with chemother-
apeutic agents. A number of these IMOs have also entered
Phase I trials (Agrawal and Kandimalla, 2007; Dynavax Technolo-
gies, 2010; Hennessy et al., 2010). Similar Immunostimulatory
sequences (ISS), comprised of short DNA sequences that have
been shown to induce production of memory T cells and a Th1
response, and are also under investigation (Agrawal and Kandi-
malla, 2007). A potential advantage of ISS is that they can be used
alone or linked to antigens to suppress Th2 response (Barry and
Cooper, 2007).
Coley Pharmaceutical Group (Wellesley, MA, USA; currently
Pﬁzer) developed CPG7909, which has been tested as a vac-
cine adjuvant in human clinical trials in the context of several
vaccines (including ﬂu, hepatitis, and malaria) with promising
results (Cooper et al., 2004a,b; Mullen et al., 2008). The immunos-
timulatory effect of CpG7909 in these vaccines was shown to
depend on the association of the CpG and antigen to alum (Aebig
et al., 2007; Mullen et al., 2007). Addition of CpG 7909 to the
malaria vaccine, AMA1-C1/alum vaccine in naïve (not exposed
to malaria) individuals was shown to elicit signiﬁcantly higher
AMA1 speciﬁc immune IgG compared to individuals who only
received AMA1-C1/alum (Mullen et al., 2008). Later studies on
these samples showed that addition of CpG 7909 enhanced the
kinetics, magnitude, and longevity of responses (Crompton et al.,
2009). In contrast the same CpG-containing malaria vaccine did
not enhance the acquisition of memory in semi-immune adults
living in Mali (Traore et al., 2009). Understanding the molecu-
lar basis of this apparent refractoriness to TLR9 agonist in the
endemic population is pertinent and of signiﬁcant interest to
vaccinology.
IMPORTANCE OF FORMULATION
Modiﬁcations to enhance vaccine potency were made early on
in vaccine development history. For instance, “lipovaccines,”
or homogenized dried bacterial cells mixed with oil, were ﬁrst
reported in 1916 (Achard and Foix, 1916; Pinoy, 1916a,b). This
vaccine formulation increased the potency of killed bacterial vac-
cines in human subjects, reducing the high doses of bacterial cells
and number of immunizations required,making them more com-
parable in efﬁcacy to vaccines based on live-attenuated organisms
such as smallpox, which only required one dose (Whitmore, 1919;
Lewis and Dodge, 1920).
Formulation effects on vaccine antigen and adjuvant efﬁcacy
continue to remain critical. For example, CpGs formulated with
particle-based platforms (i.e., alum, oil-in-water emulsion, or
polymeric particles) induces increased total antibodies and Th1
responses in a variety of disease and animal models compared
to either formulation component alone (Brazolot Millan et al.,
1998; Ott et al., 2002; Ioannou et al., 2003; Linghua et al., 2006;
Singh et al., 2007; Wack et al., 2008; Salem and Weiner, 2009; Fox
et al., 2010a,b). The most abundant data regarding the impor-
tance of seemingly subtle formulation variations involve TLR4
agonists. For instance, AS01 (a liposomal formulation containing
MPLand the saponin adjuvantQS21) inducedhigher anti-parasite
antibodies (with less reactogenicity) compared to an emulsion
formulation of the same molecules in a malaria vaccine clinical
trial (Owusu-Agyei et al., 2009). Other TLR4 agonist formu-
lation comparisons include oil-in-water emulsion vs. aqueous
suspension or alum-adsorbed; the emulsion formulation was gen-
erally superior, inducing qualitative and quantitative differences in
immune responses (Hui and Hashimoto, 2008; Lousada-Dietrich
et al., 2011).
Several leishmaniasis vaccine studies employed formulation
technologies to improve immune responses, especially liposomes.
Lipid composition clearly inﬂuences immune responses, with syn-
thetic saturated long-chain phosphatidylcholines inducing more
protective responses and greater Th1-bias than unsaturated egg
phosphatidylcholine in BALB/cmice or hamsters immunizedwith
liposomal leishmania antigens (Kahl et al., 1989; Mazumdar et al.,
2005; Badiee et al., 2009a). Liposome size, charge, and stabil-
ity can be modiﬁed by different manufacturing conditions and
additional components such as charged or PEGylated headgroups
and cholesterol. Interestingly, liposomes were shown to reduce
the toxicity of incorporated Lipid A structures (Richards et al.,
1989). Another study showed that co-encapsulation of leishmania
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antigens and adjuvant (pDNA) in liposomes increased protec-
tive efﬁcacy by twofold compared to encapsulation of only the
antigen (Mazumder et al., 2007). Likewise, coencapsulation of
leishmania antigen and CpG in polymeric nanospheres showed
the strongest protective responses in BALB/c mice compared to
other formulation variations (Tafaghodi et al., 2011). Shimizu
et al. (2007) conﬁrmed the importance of leishmania antigen
encapsulation in liposomes and augmented protective immune
responses further by targeting the liposome to mannose recep-
tors on macrophages. Liposome surface charge was also found
to affect immune responses to leishmania antigen, with neu-
tral surface charge resulting in smallest footpad swelling, lowest
splenic parasite burden, highest IgG2a/IgG1 ratio, highest IFN-
γ production, and lowest IL-4 production compared to cationic
or anionic liposomes (Badiee et al., 2009b). The above stud-
ies indicate that particulate formulations such as liposomes can
serve as adjuvants simply through improved antigen delivery
mechanisms, although co-formulation with additional immunos-
timulatory molecules may further improve immune responses
(Kasturi et al., 2011).
Other important vaccine adjuvant formulations include
ISCOMs, ISCOmatrix, and virosomes. ISCOMs, or immune-
stimulating complexes, are particulate antigen delivery system
that consists of antigen, phospholipid, cholesterol, and saponin
structures (Morein et al., 2007). ISCOMs have shown promising
adjuvant activity, and induced protective immunity in a number
of disease models, including murine CL although reactogenicity
and inefﬁcacy was reported in some studies (Papadopoulou et al.,
1998; Sjolander et al., 1998a,b; Morein et al., 2007; Middleton
et al., 2009; Clements et al., 2010). ISCOMATRIX, is a particu-
late adjuvant that has essentially the same structure of ISCOMs
but without antigen. Antigens can be formulated with the ISCO-
MATRIX to produce ISCOMATRIX vaccines that can provide
the similar antigen presentation and immunomodulatory prop-
erties as the ISCOMs but with much broader application as they
are not limited to hydrophobic membrane proteins (Sun et al.,
2009). ISCOMATRIX, is a more well-deﬁned platform that under
controlled conditions, form cage-like structures typically 40 nm
in diameter. The ISCOMATRIXTM adjuvant has been formu-
lated with a wide range of antigens to produce ISCOMATRIXTM
vaccines with great success but has not been tested in CL yet
(McKenzie et al., 2010). Virosomes, like liposomes, consist of
phospholipid vesicles. However, virosomes also include fusogenic
proteins (hemagglutinin and neuraminidase) for enhanced
antigen processing (Metcalfe and Gluck, 2006). Inﬂexal V
(inﬂuenza) and Epaxal (hepatitis A) are virosome-based vac-
cines manufactured by Crucell and approved for use in many
countries.
In order to optimize vaccine formulations, an array of parame-
ters must be investigated. Formulation manufacturability and cost
are often taken for granted or not considered in early development
stages. However, these factors can play a critical role in ultimate
product success (Hilleman, 1966, 1999). Other important factors
include particle size, degradability, shape, stability, and release
kinetics (Mueller et al., 2004; Garidel et al., 2005; Mohanan et al.,
2010). Numerous challenges remain related to adjuvant develop-
ment, especially in the context of neglected tropical diseases such
as leishmaniasis, but these can be overcome by using a systematic
approach.
SUMMARY
Experimental CL has become a standard for investigating the
development of T helper cell response and is now well estab-
lished as the classic textbook example of the Th1/Th2 paradigm.
Alongside the rapid advances in PRR discovery, this model has
served to signiﬁcantly advance our understanding of vaccine adju-
vants. In the current era of translational biology, it is therefore
ironic that few agonists (only those engaging TLR4 and TLR 7/8)
have advanced into clinical trials against leishmania infection of
humans (Table 1). Regardless, it is our hope that the advance-
ment of vaccine adjuvants and improved understanding of the
clinical situation will ultimately combine to develop effective tools
to control leishmaniases.
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